Farnaz Tabatabaian, MD, MS, associate professor, Division of Allergy & Immunology, Department of Internal Medicine, USF Health Morsani College of Medicine, provides background on mast cell biology and discusses mastocytosis presentation. Dr Tabatabaian also reviews current and emerging therapeutic options for patients.
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
In this detailed webinar on systemic mastocytosis, Dr. Miti introduces Professor Prithviraj Bose, an expert in the field, who discusses the complexities of diagnosing and managing systemic mastocytosis…